Shares of pharma company Wanbury climbed nearly 4 per cent on Friday after the company received an EIR with zero form 483 observations, from the USFDA
Going ahead in FY25, the management anticipates an improvement in margins, mostly driven by an anticipated growth in export sales and backward integration.
The northward movement in the rally follows the announcement of a whopping 350 per cent dividend, or Rs 35 per share, for FY24
The rise in the share price came after the company announced that its unit, Glenmark Therapeutics Inc, USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent.
The drop in the share price came after the company announced that its' arm Eugia Pharma Specialties' Unit-III received a warning letter from United States Food and Drug Administration (USFDA).
The US & North America Formulation biz reported growth of 29.8% YoY in Q1FY25, on account of incremental revenue from new product launches, and increase in the share of existing customers.
The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).
The inspection at the Hyderabad facility took place between July 25, 2024 and August 02, 2024.
Neuland Laboratories hit a new high of Rs 11,093.15, as the stock rallied 18% on the BSE in Friday's intra-day trade on the back of robust earnings for June 2024 quarter.
Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.
Brokerages expect a satisfactory quarter for Sun Pharma giant with a steady growth in the topline as well as bottomline on a year-on-year (YoY) basis, however, sequentially the bottomline may get hit
Shares of Torrent Pharma slumped up to 4.26 per cent at Rs 646.70 per share on the BSE in Tuesday's intraday deals. This came despite the Indian drugmaker delivering a strong April-June quarter
The fall in the stock came after the company announced that it has secured an Official Action Indicated (OAI) report from the United States Food and Drug Administration (USFDA).
In the past one year, the stock has zoomed 89 per cent, as compared to 21 per cent rally in the BSE Sensex.
Shilpa Medicare hit a multi-year high of Rs 672.50, rallied 16% after the company's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order.
5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.
The management expects to sustain US business at the $200 million plus level, going ahead with the continued ramp-up of Tiotropium and new product launches in fiscal year 2024-25.
Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.
At 9:55 AM, the shares were off highs, trading 2.25 per cent higher at Rs 163.95 per share. In comparison, BSE Sensex was trading 0.16 per cent lower at 77,211.40 levels.
The surge came after Suven Pharmaceuticals said that it has entered into a definitive agreement to acquire a controlling stake of Sapala Organic for Rs 229.5 crore, in an all cash deal